Resultados: 72

“Smart” analysis of the landmark trial - early outcomes with latest generation tavi valves in patients with a small aortic annulus

JACC cardiovasc. interv; 18 (4 Suppl. S), 2025
BACKGROUND Among patients with severe aortic stenosis (AS) un- dergoing transcatheter aortic valve implantation (TAVI), nearly one third have a small aortic annulus. These patients are at higher risk of prosthetic valve dysfunction. Recently, the SMART trial reported that the self-expanding Evolut series...

Penetrance of TAVR in latin america compared with north america and europe - insight from biba medtech registry

JACC cardiovasc. interv; 18 (4 Suppl. S), 2025
BACKGROUND Since its commercialization in 2007, the number of transcatheter aortic valve replacement (TAVR) procedures has grown exponentially worldwide. The penetrance of TAVR in Latin America compared to North America and Europe, remains unknown. We sought to examine the penetrance of TAVR in Latin Ame...

Early outcomes of the novel Myval THV series compared to SAPIEN THV series and Evolut THV series in individuals with severe aortic stenosis

EuroIntervention; 21 (2), 2025
BACKGROUND: There are limited head-to-head randomised trials comparing the performance of different transcatheter heart valves (THVs).AIMS: We aimed to evaluate the non-inferiority of the balloon-expandable Myval THV series compared to the balloon-expandable SAPIEN THV series or the self-expanding Evolut...

Safety and feasibility of a single-artery access for TAVR: initial clinical experience

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
INTRODUCTION: Bicuspid aortic valve (BAV) is the most common congenital cardiac abnormality, occurring in 1% to 2% of the total population and can reach up to 25% in patients (pts) aged 80 years or older referred for TAVI. However, this condition has been excluded from major randomized studies. Recently,...

Assistência de enfermagem a pacientes submetidos a implante transcateter de prótese aórtica com sistema de proteção embólica cerebral
Nursing care for patients undergoing transcatheter implantation of an aortic prosthesis with a cerebral embolic protection system

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
INTRODUÇÃO: O Implante Transcateter de Prótese Aórtica (TAVI) é uma prática crescente na cardiologia, mas o Acidente Vascular Cerebral (AVC) é uma complicação significativa. O filtro de proteção embólica cerebral vem sendo estudado em pacientes submetidos à TAVI. OBJETIVO(s): Avaliar o plane...

Characteristics and clinical outcomes in patients deemed ineligible for TAVR

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has emerged as a standard therapy for patients (pts) with severe symptomatic aortic stenosis (AS). Its indications have expanded from high-surgical to low-surgical risk pts. However, some pts may be not eligible for the procedure due to clinical a...

Impacto clínico da diferença entre os sexos e local de realização de procedimento no implante transcateter de válvula aórtica: dados do Registro RIBAC-NT
Clinical impact of the difference between sexes and location of procedure in transcatheter aortic valve implantation: data from the RIBAC-NT Registry

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
INTRODUÇÃO: Implante transcateter de válvula aórtica (TAVI) é o tratamento de escolha para pacientes com estenose aórtica acima de 70 anos de idade com anatomia favorável. No entanto, o impacto das diferenças de entre os sexos e local de realização do procedimento (público versus privado) nos ...

Outcomes of Transcatheter Aortic Valve Implantation (TAVI) in patients with bicuspid aortic valve: a single-center experience

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
INTRODUCTION: Bicuspid aortic valve (BAV) is the most common congenital cardiac abnormality, occurring in 1% to 2% of the total population and can reach up to 25% in patients (pts) aged 80 years or older referred for TAVI. However, this condition has been excluded from major randomized studies. Recently,...

Mid-term outcomes following transcatheter aortic valve replacement with meril myval

Int. j. cardiovasc. sci. (Impr.); 37 (suppl. 13), 2024
BACKGROUND: TAVR has emerged as a revolutionary treatment for patients with symptomatic and severe AS, irrespective of surgical-risk scores. Novel transcatheter heart valves (THV) with a lower profile, easy of use and expected longer durability are being developed to target younger patients. Myval is a 1...

Efficacy and safety of leadless pacemaker implantation post transcatheter aortic valve replacement: asystematic review and single-arm meta-analysis

Int. j. cardiovasc. sci. (Impr.); 37 (suppl.9), 2024
BACKGROUND: The leadless pacemaker has emerged as a promising alternative for patients requiring artificial cardiac stimulation. Advanced atrioventricular block (AVB) is the primary indication for leadless pacemaker (LP) implantation in patients who have undergone transcatheter aortic valve replacement (...